Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDMaxCyte, Inc. Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2024 | 1 | -$0.13 | -$0.12 | -$0.13 |
| Q2 2024 | 1 | -$0.13 | -$0.12 | -$0.12 |
| Q3 2024 | 1 | -$0.13 | -$0.12 | -$0.12 |
| Q4 2024 | 2 | -$0.13 | -$0.10 | -$0.12 |
| Q1 2025 | 2 | -$0.12 | -$0.11 | -$0.11 |
| Q2 2025 | 1 | -$0.11 | -$0.10 | -$0.10 |
| Q3 2025 | 1 | -$0.10 | -$0.09 | -$0.09 |
| Q4 2025 | 1 | -$0.10 | -$0.09 | -$0.10 |
| Q1 2026 | 1 | -$0.10 | -$0.09 | -$0.10 |
| Q2 2026 | 1 | -$0.10 | -$0.09 | -$0.09 |
| Q3 2026 | 1 | -$0.08 | -$0.08 | -$0.08 |
| Q4 2026 | 1 | -$0.08 | -$0.07 | -$0.07 |
MaxCyte, Inc. Earnings Date And Information
MaxCyte, Inc. last posted its earnings results on Wednesday, November 6th, 2024. The company reported $-0.11 earnings per share for the quarter, topping analysts' consensus estimates of $-0.13 by $0.02. The company had revenue of 8.16 M for the quarter and had revenue of 41.29 M for the year. MaxCyte, Inc. has generated $0 earnings per share over the last year ($-0.37 diluted earnings per share) and currently has a price-to-earnings ratio of -12.47. MaxCyte, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, March 11th, 2025 based on prior year's report dates.
MaxCyte, Inc. Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 11/06/2024 | Q3 2024 | -$0.13 | -$0.11 | 0.02 | $7.46 M | $8.16 M |
| 08/06/2024 | Q2 2024 | -$0.14 | -$0.09 | 0.05 | $7.97 M | $10.43 M |
| 05/07/2024 | Q1 2024 | -$0.14 | -$0.09 | 0.05 | $11.34 M | |
| 03/12/2024 | Q4 2023 | -$0.10 | -$0.05 | 0.05 | $15.67 M | |
| 11/08/2023 | Q3 2023 | -$0.10 | -$0.11 | -0.01 | $8.87 M | $8.00 M |
| 08/09/2023 | Q2 2023 | -$0.10 | -$0.10 | 0 | $10.66 M | $9.04 M |
| 05/10/2023 | Q1 2023 | -$0.11 | -$0.08 | 0.03 | $8.58 M | |
| 03/15/2023 | Q4 2022 | -$0.06 | -$0.03 | 0.03 | $12.42 M | |
| 11/09/2022 | Q3 2022 | -$0.09 | -$0.06 | 0.03 | $10.43 M | $10.64 M |
| 08/10/2022 | Q2 2022 | -$0.08 | -$0.08 | 0 | $9.23 M | $9.61 M |
| 05/09/2022 | Q1 2022 | -$0.07 | -$0.04 | 0.03 | $11.59 M | |
| 03/22/2022 | Q4 2021 | -$0.05 | -$0.05 | 0 | $10.15 M | |
| 11/10/2021 | Q3 2021 | -$0.05 | -$0.03 | 0.02 | $7.28 M | $10.14 M |
| 09/13/2021 | Q2 2021 | -$0.05 | -$0.05 | -0 | $5.79 M | $7.11 M |
| 03/31/2021 | Q1 2021 | -$0.09 | $6.49 M | |||
| 12/30/2020 | Q4 2020 | -$0.03 | $8.51 M | |||
| 09/29/2020 | Q3 2020 | -$0.04 | $6.76 M | |||
| 06/29/2020 | Q2 2020 | -$0.05 | $13.39 M | $5.15 M | ||
| 03/30/2020 | Q1 2020 | -$0.05 | $5.74 M | |||
| 12/30/2019 | Q4 2019 | -$0.03 | $6.62 M |
MaxCyte, Inc. Earnings: FAQ's
When is MaxCyte, Inc.'s earnings date?
MaxCyte, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, March 11th, 2025 based off last year's report dates.
Did MaxCyte, Inc. beat their earnings estimates last
quarter?
In the previous quarter, MaxCyte, Inc. (:MXCT) reported $-0.11 earnings per share (EPS) to beat the analysts' consensus estimate of $-0.13 by $0.02.
How can I listen to MaxCyte, Inc.'s earnings conference
call?
The conference call for MaxCyte, Inc.'s latest earnings report can be listened to online.
How can I read MaxCyte, Inc.'s conference call transcript?
The conference call transcript for MaxCyte, Inc.'s latest earnings report can be read online.
How much revenue does MaxCyte, Inc. generate each year?
MaxCyte, Inc. (:MXCT) has a recorded annual revenue of $41.29 M.
How much profit does MaxCyte, Inc. generate each year?
MaxCyte, Inc. (:MXCT) has a recorded net income of $41.29 M. MaxCyte, Inc. has generated $-0.37 earnings per share over the last four quarters.
What is MaxCyte, Inc.'s price-to-earnings ratio?
MaxCyte, Inc. (:MXCT) has a price-to-earnings ratio of -12.47 and price/earnings-to-growth ratio is -0.12.